Two New Drugs Approved for Non-Small Cell Lung Cancer.

The Food and Drug Administration (FDA) has approved capmatinib (Tabrecta) for the treatment of metastatic non-small cell lung cancer in adults whose tumors have a mutation leading to mesenchymal-epithelial transition exon 14 skipping.Nurses should monitor patients for serious adverse effects such as interstitial lung disease/pneumonitis, hepatotoxicity, pancreatic toxicity, photosensitivity, and embryo-fetal toxicity.The FDA has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of unresectable or metastatic non-small cell lung cancer in adults whose tumors have activating human epidermal growth factor receptor 2 mutations and who have received a prior systemic therapy.Enhertu carries a boxed warning regarding the risk of interstitial lung disease and embryo-fetal toxicity.